1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Respiratory Diagnostics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing aging population with susceptibility to chronic respiratory diseases
5.1.1.2. Growth in the approvals for respiratory disease diagnostic kits, tests, and systems
5.1.1.3. Rising preferences for remote and home care testing devices
5.1.2. Restraints
5.1.2.1. Incidences of product recall of respiratory diagnosis panels and kits with limited reimbursement policies
5.1.3. Opportunities
5.1.3.1. Technological advancements to introduce sophisticated respiratory diagnostic tools
5.1.3.2. Government initiatives and funding for respiratory diagnostic tools
5.1.4. Challenges
5.1.4.1. Risk of errors associated with complex diagnostic procedures
5.2. Market Segmentation Analysis
5.2.1. Product: Need for rapid detection of pathogens driving the adoption of assays and reagents
5.2.2. Test Type: Research initiatives to advance the accuracy and specificity of molecular diagnostic tests
5.2.3. Indication: Need for advanced respiratory diagnostic technologies to attain accurate testing of chronic obstructive pulmonary disease
5.2.4. End-User: Adoption of a diverse range of diagnostic tools in hospitals and clinics for identifying and monitoring respiratory ailments
5.3. Market Trend Analysis
5.3.1. Significant market growth potential driven by investments in healthcare infrastructure and supportive regulatory landscape in the Americas region
5.3.2. Massive need of early detection and respiratory diagnostic solutions to monitor and manage viral respiratory infections in APAC
5.3.3. Well-established respiratory diagnostics development across EMEA enabling the provision of advanced testing capabilities for government and private disease screening activities
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Respiratory Diagnostics Market, by Product
6.1. Introduction
6.2. Assays & Reagents
6.3. Instruments & Devices
6.4. Software & Services
7. Respiratory Diagnostics Market, by Test Type
7.1. Introduction
7.2. Imaging Tests
7.3.1. Computed Tomography
7.3.2. Magnetic Resonance Imaging
7.3.3. Positron Emission Tomography
7.3.4. X-Ray
7.3. Mechanical Tests
7.4.1. Peak Flow Test
7.4.2. Pulmonary Function Tests
7.4.3. Spirometry
7.4. Molecular Diagnostic Tests
7.5.1. DNA Sequencing & Next-Generation Sequencing
7.5.2. In Situ Hybridization
7.5.3. Microarrays
7.5.4. Nucleic Acid Amplification Test
7.5.5. PCR
7.5. OSA Diagnostic Tests
7.6. Traditional Diagnostic Tests
7.7.1. Biochemical Tests
7.7.2. Immunodiagnostics
7.7.3. Microscopy
8. Respiratory Diagnostics Market, by Indication
8.1. Introduction
8.2. Asthma
8.3. Chronic Obstructive Pulmonary Disease
8.4. Lung Cancer
8.5. Pneumonia
8.6. Tuberculosis
9. Respiratory Diagnostics Market, by End-User
9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Hospitals & Clinics
9.4. Research Institutes
10. Americas Respiratory Diagnostics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Respiratory Diagnostics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Respiratory Diagnostics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Merger & Acquisition
13.3.1.1. ResMed Acquires Sleep and Respiratory Diagnostics Software Maker Somnoware
13.3.2. Agreement, Collaboration, & Partnership
13.3.2.1. NYU Langone Health Enters 8-Year Partnership with Philips
13.3.2.2. Thermo Fisher partners with ALPCO-GeneProof to Broaden Their CE-IVD Molecular Assay Portfolio
13.3.2.3. SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience
13.3.2.4. Philips and Masimo Expand Partnership To Improve Telehealth For Patients And Clinicians Around The World
13.3.3. New Product Launch & Enhancement
13.3.3.1. QIAGEN Launches QIAstat-Dx in Japan with Respiratory Panel for Syndromic Testing
13.3.3.2. Molbio Diagnostics adds Truenat H3N2/H1N1 Test to Respiratory Disease Portfolio
13.3.3.3. Vitalograph Launches New Respiratory VitaloPFT Series
13.3.4. Award, Recognition, & Expansion
13.3.4.1. Masimo Gets De Novo Approval From FDA for ORi
13.3.4.2. bioMérieux Submits Dual 510(k) and CLIA-Waiver Application to FDA for the BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel
13.3.4.3. BD Receives 510(k) Clearance for COVID-19, Influenza A/B, RSV Molecular Combination Test
13.3.4.4. Seegene Obtains IVDR Certification for 30 Diagnostic Assays
13.3.4.5. Hologic Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Adaltis S.r.l.
14.1.3. Altona Diagnostics GmbH
14.1.4. Becton, Dickinson, and Company
14.1.5. Bio-Rad Laboratories, Inc.
14.1.6. bioMérieux S.A.
14.1.7. Bioneer Corporation
14.1.8. CerTest Biotec S.L.
14.1.9. Daan Gene Co., Ltd.
14.1.10. Diatech Pharmacogenetics srl
14.1.11. Drägerwerk AG & Co. KGaA
14.1.12. F. Hoffmann-La Roche Ltd.
14.1.13. GE HealthCare Technologies, Inc.
14.1.14. Hologic, Inc.
14.1.15. Johnson & Johnson Services, Inc.
14.1.16. Koninklijke Philips N.V.
14.1.17. Masimo Corporation
14.1.18. Medtronic PLC
14.1.19. Merck KGaA
14.1.20. ProAxsis by NetScientific PLC
14.1.21. Quest Diagnostics Incorporated
14.1.22. Quidel Corporation
14.1.23. Sansure Biotech Inc.
14.1.24. SDI Diagnostics, Inc.
14.1.25. Seegene Inc.
14.1.26. Siemens Healthineers AG
14.1.27. Somnoware by ResMed Corp.
14.1.28. Thermo Fisher Scientific Inc.
14.1.29. Vitalograph Ltd.
14.1.30. ZeptoMetrix LLC
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing